Associated Papers
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
George TJ et al.
Jco Precision Oncology, 2024
A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed/refractory AITL.
Ricard L et al.
Frontiers in Immunology, 2024
Defective migration and dysmorphology of neutrophil granulocytes in atypical chronic myeloid leukemia treated with ruxolitinib.
Bornemann L et al.
Bmc Cancer, 2020
Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features.
Manso R et al.
Oncotarget, 2018
29662631 (PubMed )
Supplement: oncotarget-09-16124-s002.xls › Supplementary_Table_3
CD133 marks a stem cell population that drives human primary myelofibrosis.
Triviai I et al.
Haematologica, 2015
Select a paper to view details